Search by Drug Name or NDC

    NDC 00069-1029-02 XELJANZ 1 mg/mL Details

    XELJANZ 1 mg/mL

    XELJANZ is a ORAL SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is TOFACITINIB CITRATE.

    Product Information

    NDC 00069-1029
    Product ID 0069-1029_b66d67c5-58ad-437e-a098-1e4a18d1104d
    Associated GPIs 66603065102020
    GCN Sequence Number 081537
    GCN Sequence Number Description tofacitinib citrate SOLUTION 1 MG/ML ORAL
    HIC3 Z2Z
    HIC3 Description JANUS KINASE (JAK) INHIBITORS
    GCN 48684
    HICL Sequence Number 039768
    HICL Sequence Number Description TOFACITINIB CITRATE
    Brand/Generic Brand
    Proprietary Name XELJANZ
    Proprietary Name Suffix n/a
    Non-Proprietary Name tofacitinib
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form SOLUTION
    Route ORAL
    Active Ingredient Strength 1
    Active Ingredient Units mg/mL
    Substance Name TOFACITINIB CITRATE
    Labeler Name Pfizer Laboratories Div Pfizer Inc
    Pharmaceutical Class Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA213082
    Listing Certified Through 2024-12-31

    Package

    NDC 00069-1029-02 (00069102902)

    NDC Package Code 0069-1029-02
    Billing NDC 00069102902
    Package 1 BOTTLE in 1 CARTON (0069-1029-02) / 240 mL in 1 BOTTLE (0069-1029-01)
    Marketing Start Date 2021-02-08
    NDC Exclude Flag N
    Pricing Information N/A